BALAMINES - Balaji Amines
📢 Recent Corporate Announcements
Balaji Amines has reported a significant disruption in its supply chain due to the ongoing Middle East conflict, which has severely impacted global shipping and logistics. Key suppliers of Ammonia, a critical raw material for the company, have invoked Force Majeure clauses following a shortage of Liquefied Natural Gas (LNG). As a result, several of the company's manufacturing plants are currently non-operational, affecting the production of Methylamines and Ethylamines. While the company is exploring alternative supply sources, the total financial and operational impact remains unquantifiable at this stage.
- Middle East conflict has led to Force Majeure invocations by key Ammonia suppliers.
- Shortage of LNG has halted Ammonia production for several Indian manufacturers.
- Multiple manufacturing plants of Balaji Amines are currently non-operational due to raw material unavailability.
- Production of core products including Methylamines, Ethylamines, and derivatives is significantly affected.
- The company is unable to estimate the exact financial impact of the shutdown at this time.
Balaji Amines Limited has announced the cancellation of its plant visit and management meeting with investors and analysts, which was originally scheduled for March 13, 2026. The company cited unavoidable circumstances for the cancellation of the event, which was previously intimated on February 27, 2026. Such meetings are typically used by institutional investors to gain operational insights, and this delay postpones that engagement. No new date for the visit or meeting has been provided in the current disclosure.
- Cancellation of the plant visit and management meet scheduled for March 13, 2026
- The event was originally announced to the exchanges on February 27, 2026
- Company cited 'unavoidable circumstances' as the reason for the cancellation
- No alternative date has been proposed in the current regulatory filing
Balaji Amines Limited has announced a physical plant visit and management interaction for analysts and institutional investors scheduled for March 13, 2026. The event will be held at the company's facility in Solapur, Maharashtra, to provide insights into operational processes. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during these discussions. Such visits are standard practice for institutional engagement and transparency.
- Physical plant visit and investor meet scheduled for March 13, 2026
- Location of the event is Solapur, Maharashtra
- Discussions will be strictly based on publicly available information
- Participation includes various analysts and institutional investors
Balaji Amines reported a mixed Q3FY26 with consolidated revenue growing 4.9% YoY to ₹336.29 crore, though it declined 3.26% sequentially. While EBITDA grew 15.12% YoY to ₹61.67 crore with margins expanding to 18.34%, PAT saw a slight YoY dip of 1.22% to ₹30.76 crore. Total sales volumes increased to 25,894 MT from 24,097 MT YoY, driven by steady demand in specialty chemicals and amines. The company is aggressively pursuing a ₹750 crore expansion in its subsidiary and expects several new plants to commission in FY27.
- Consolidated Revenue grew 4.9% YoY to ₹336.29 Cr, supported by a volume increase to 25,894 MT.
- EBITDA margins improved to 18.34% from 16.71% YoY, despite a 7.78% QoQ drop in EBITDA.
- PAT for Q3FY26 stood at ₹30.76 Cr, reflecting a 17.09% sequential decline due to higher tax and depreciation.
- Methylamines capacity successfully expanded to 88,000 TPA; ₹750 Cr expansion underway in subsidiary for HCN and EDTA products.
- Standalone entity remains zero-debt, with all new projects funded through internal accruals.
Balaji Amines reported a consolidated revenue of ₹336.29 crore for Q3FY26, a slight decline from ₹347.61 crore in the previous quarter. Net profit for the quarter stood at ₹30.76 crore, down from ₹37.10 crore in Q2FY26, with EBITDA margins contracting to 18.34%. Despite near-term pressure from the pharma and agrochemical segments, the company is moving ahead with a ₹750 crore expansion plan in its subsidiary, which has received 'Mega Project' status. Several new plants, including DME and Acetonitrile, are expected to be commissioned in FY 2026-27.
- Consolidated PAT for Q3FY26 decreased to ₹30.76 crore from ₹37.10 crore in Q2FY26.
- EBITDA margin stood at 18.34% for the quarter, compared to 19.24% in the previous quarter.
- Total sales volume for Q3FY26 was 25,894.09 MT, with Specialty Chemicals accounting for 9,678.27 MT.
- Announced a ₹750 crore phased expansion in subsidiary Balaji Speciality Chemicals for products like Sodium Cyanide and EDTA.
- The company maintains a zero-debt status on a standalone basis, funding projects through internal accruals.
Balaji Amines reported a mixed performance for Q3 FY26, with consolidated revenue growing 5.9% YoY to ₹331.30 crore but declining 2.7% sequentially. Profitability faced significant pressure as consolidated PAT fell 17% QoQ to ₹30.76 crore, impacted by higher raw material costs and increased finance charges. The core Amines & Speciality Chemicals segment remains the primary driver, contributing over 97% of total revenue. On a nine-month basis, PAT stands at ₹104.39 crore, down from ₹118.15 crore in the previous year, indicating a challenging margin environment.
- Consolidated Revenue from operations stood at ₹331.30 crore, a 5.9% increase compared to ₹312.73 crore in Q3 FY25.
- Consolidated Net Profit (PAT) dropped to ₹30.76 crore, down 17% from ₹37.10 crore in the preceding quarter.
- Earnings Per Share (EPS) for the quarter decreased to ₹9.49 from ₹10.24 in the same period last year.
- The Amines & Speciality Chemicals segment reported a profit before tax of ₹41.99 crore, down from ₹49.38 crore in Q2 FY26.
- Total consolidated expenses for the quarter rose to ₹290.31 crore, reflecting margin compression compared to the previous quarter.
Balaji Amines has received an Eligibility Certificate from the Government of Maharashtra for its Unit-4 expansion under the Mega Projects scheme. The company is entitled to incentives totaling ₹258.01 crore over a seven-year period ending December 2030. These incentives include a 50% SGST subsidy on sales within Maharashtra, along with exemptions from electricity and stamp duties. This development is expected to significantly lower operational costs and improve the net profitability of the Unit-4 facility.
- Total incentive entitlement of ₹258.01 crore under the Package Scheme of Incentives-2013
- Incentives are valid for a 7-year period from January 1, 2024, to December 31, 2030
- Entitlement includes 50% Industrial Promotion Subsidy (IPS) on SGST payable for sales in Maharashtra
- Provides 100% exemption from Stamp Duty and full Electricity Duty exemption for the unit
Balaji Amines Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the period ended December 31, 2025. The document confirms that the Registrar and Share Transfer Agent, Venture Capital and Corporate Investments Private Limited, processed all dematerialization requests within the mandated 15-day window. This process includes the mutilation and cancellation of physical share certificates and updating the records of NSDL and CDSL. This is a standard administrative filing required by all listed entities in India to ensure the integrity of electronic shareholding records.
- Compliance certificate issued for the quarter ended December 31, 2025.
- Confirmation that dematerialization requests were processed within 15 days of receipt.
- Verification and cancellation of physical certificates completed as per SEBI guidelines.
- Registrar and Share Transfer Agent (RTA) involved is Venture Capital and Corporate Investments Private Limited.
Balaji Amines Limited has announced the closure of its trading window for all designated persons starting January 1, 2026. This move is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the release of financial results for the quarter and nine months ending December 31, 2025. The window will remain closed until 48 hours after the financial results are officially declared. The specific date for the board meeting to approve these results will be communicated to the exchanges at a later date.
- Trading window closure effective from January 1, 2026, for all designated persons.
- Closure is related to the upcoming Un-audited Financial Results for the period ended December 31, 2025.
- Window to reopen 48 hours after the public declaration of the financial results.
- The board meeting date for results approval is yet to be announced.
Financial Performance
Revenue Growth by Segment
Total volumes for Q2 FY26 were 26,165 MT, broadly steady YoY. Segment volumes: Amines (7,685 MT), Amines Derivatives (8,374 MT), and Specialty Chemicals (10,107 MT). Consolidated revenue for Q2 FY26 stood at INR 341 Cr, a 4.7% decline from INR 358 Cr in Q1 FY26.
Geographic Revenue Split
Not disclosed in available documents, though the company utilizes export earnings as a natural hedge against foreign exchange risks.
Profitability Margins
Profitability showed resilience with Q2 FY26 PAT at INR 37 Cr, flat QoQ. PAT margin for H1 FY26 stood at 10%. Standalone PAT margin for Q2 FY26 was 11%, down from 12% YoY.
EBITDA Margin
EBITDA margin improved to 19% in Q2 FY26 from 17% in Q1 FY26, driven by efficient operations despite a 4% YoY decline in absolute EBITDA to INR 67 Cr.
Capital Expenditure
The company capitalized INR 147.72 Cr in FY25. Current Capital Work-in-Progress (CWIP) totals INR 289 Cr, including INR 116 Cr at subsidiary Balaji Speciality Chemicals Ltd (BSCL) for greenfield expansion and INR 173 Cr across other units for DME and NMM projects.
Credit Rating & Borrowing
Not disclosed in available documents; however, the company maintains a zero-debt status on a standalone basis with minimal consolidated finance costs of INR 1 Cr per quarter.
Operational Drivers
Raw Materials
Major raw materials (specific chemical names not listed) accounted for INR 185 Cr in Q2 FY26, representing 53.1% of total revenue.
Import Sources
Not disclosed in available documents, though the company imports major raw materials in bulk quantities.
Key Suppliers
Not disclosed in available documents; procurement is managed through spot prices and annual contracts.
Capacity Expansion
Unit 4 Greenfield Phase 2 & 3 capex is scheduled for completion by FY 2026. New plants commissioned include Methylamines and N-Butylamine (Unit IV).
Raw Material Costs
Raw material costs were INR 185 Cr in Q2 FY26, a 1.6% decrease from INR 188 Cr YoY. Procurement strategies include bulk contracting to gain price advantages.
Manufacturing Efficiency
Maintained steady volumes of 26,165 MT in Q2 FY26 despite moderated demand in end-user segments, reflecting high operational efficiency.
Strategic Growth
Expected Growth Rate
7.80%
Growth Strategy
Growth will be driven by the completion of Unit 4 Greenfield Phase 2 & 3 by FY26, the commissioning of the Dimethyl Ether (DME) and N-Methyl Morpholine (NMM) plants, and expansion into advanced chemicals like HCN, NaCN, and EDTA at the BSCL subsidiary.
Products & Services
Methylamines, N-Butylamine, Dimethyl Ether (DME), N-Methyl Morpholine (NMM), Iso Propyl Amine, HCN, NaCN, EDTA, and EDTA-Na.
Brand Portfolio
Balaji Amines, Balaji Speciality Chemicals Limited, and Balaji Sarovar Premiere (Hospitality).
New Products/Services
New launches include DME, NMM, and Iso Propyl Amine; revenue contribution percentages are not yet disclosed as projects are under development.
Market Expansion
Targeting advanced chemical sectors through greenfield and brownfield expansions at Unit 4 and BSCL with a timeline extending through FY26.
External Factors
Industry Trends
The Amines market is projected to grow at a CAGR of 7.8% from 2024 to 2030, reaching US$23.5 billion, driven by critical demand in healthcare and agriculture.
Competitive Moat
Moat is built on a diversified product portfolio, integrated manufacturing capabilities, and a zero-debt standalone balance sheet, providing high financial flexibility for expansion.
Macro Economic Sensitivity
Sensitive to demand cycles in the pharmaceutical and agrochemical industries, which are primary end-user sectors.
Regulatory & Governance
Industry Regulations
Compliance with Ind AS 115 (Revenue) and Ind AS 16 (PPE) standards; adherence to Companies Act 2013 and SEBI Listing Regulations as confirmed by secretarial audits.
Taxation Policy Impact
Effective tax rate for Q2 FY26 was approximately 28.8% (INR 15 Cr tax on INR 52 Cr PBT).
Risk Analysis
Key Uncertainties
Volatility in raw material prices (53% of revenue) and demand fluctuations in the pharma and agrichem segments are primary risks to margin stability.
Third Party Dependencies
Dependency on external suppliers for major raw materials, though mitigated by bulk annual contracts.
Technology Obsolescence Risk
Not disclosed in available documents; company is investing in new facilities like DME and NMM to stay current.